Clinical Trials Market Size, Share & Trends Report

Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Indication, By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Jun, 2021
  • Base Year for Estimate: 2020
  • Report ID: GVR-1-68038-975-3
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 120

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                        1.1.1. Phase
                        1.1.2. Study Design
                        1.1.3. Indication
                        1.1.4. Regional scope
                        1.1.5. Estimates and forecast timeline
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased database
                        1.3.2. GVR’s internal database
                        1.3.3. Secondary sources
                        1.3.4. Primary research
                    1.4. Information or Data Analysis
                        1.4.1. Data analysis models
                    1.5. Market Formulation & Validation
                    1.6. Model Details
                        1.6.1. Commodity flow analysis (Model 1)
                            1.6.1.1. Approach 1: Commodity flow approach
                    1.7. List of Secondary Sources
                    1.8. List of Primary Sources
                    1.9. Objectives
                        1.9.1. Objective 1: Understanding the market dynamics
                        1.9.2. Objective 2: Understanding the market estimates and forecasts
                        1.9.3. Objective 3: Understanding the attributes such as strategy framework, competitor categorization
                        1.9.4. Objective 4: Understanding the key product and application scopes to conclude on the market size
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
                    3.1. Market Lineage outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Penetration & Growth Prospect Mapping
                    3.3. Product Pipeline Analysis, by Stage
                        3.3.1. Therapeutics in development
                        3.3.2. Vaccines in development
                    3.4. Fast track of clinical trials
                        3.4.1. FDA initiative - CTPA
                        3.4.2. U.K. initiative - ACCORD
                        3.4.3. ASIA Pacific initiative - DCGI
                        3.4.4. University of Pittsburgh School of Medicine-UPMC
                    3.5. Solidarity clinical trials
                        3.5.1. Participation in solidarity trials
                        3.5.2. Solidarity clinical trial for vaccines
                    3.6. Virtual clinical trials
                        3.6.1. In-home clinical services
                    3.7. COVID-19 impact on clinical trials
                        3.7.1. Companies with phase 1 trial disruption
                        3.7.2. Companies with phase 2 trial disruption
                        3.7.3. Companies with phase 3 trial disruption
                    3.8. Market Dynamics
                        3.8.1. Market Driver Analysis
                            3.8.1.1. Increasing research and development promoting outsourcing
                            3.8.1.2. Adoption of new technology in clinical research
                            3.8.1.3. Increasing prevalence of chronic disease
                            3.8.1.4. Globalization of clinical trials
                        3.8.2. Market Restraint Analysis
                            3.8.2.1. Stringent regulatory policies for patient enrollment
                            3.8.2.2. Lack of skilled workforce in clinical research
                        3.8.3. Industry Challenges
                            3.8.3.1. Rising cost of clinical trial
                    3.9. Clinical Trials: Market Analysis Tools
                        3.9.1. Industry Analysis - Porter’s
                            3.9.1.1. Supplier Power
                            3.9.1.2. Buyer Power
                            3.9.1.3. Substitution Threat
                            3.9.1.4. Threat from new entrant
                            3.9.1.5. Competitive rivalry
                        3.9.2. PESTEL Analysis
                            3.9.2.1. Political Landscape
                            3.9.2.2. Environmental Landscape
                            3.9.2.3. Social Landscape
                            3.9.2.4. Technology Landscape
                            3.9.2.5. Legal Landscape
                        3.9.3. Major Deals & Strategic Alliances Analysis
Chapter 4. Clinical Trials Market: Segment Analysis, By Phase, 2016-2028 (USD Million)
                    4.1. Definitions & Scope
                    4.2. Phase market share analysis, 2020 & 2028
                    4.3. Segment Dashboard
                    4.4. Global Clinical Trials Market, by Phase, 2016 to 2028
                    4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028for the following
                        4.5.1. Phase I
                        4.5.2. Phase II
                        4.5.3. Phase III
                        4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2016 - 2028 (USD Million)
                    5.1. Definitions & Scope
                    5.2. Study Design Market Share Analysis, 2020 & 2028
                    5.3. Segment Dashboard
                    5.4. Global Clinical Trials Market, By Study Design, 2016 to 2028
                    5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
                        5.5.1. Interventional
                        5.5.2. Observational
                        5.5.3. Expanded Access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2016 - 2028 (USD Million)
                    6.1. Definitions & Scope
                    6.2. Indication Market Share Analysis, 2020 & 2028
                    6.3. Segment Dashboard
                    6.4. Global Clinical Trials Market, By Indication, 2016 to 2028
                    6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
                        6.5.1. Autoimmune/inflammation
                        6.5.2. Pain management
                        6.5.3. Oncology
                        6.5.4. CNS condition
                        6.5.5. Diabetes
                        6.5.6. Obesity
                        6.5.7. Cardiovascular
                        6.5.8. Others
Chapter 7. Clinical Trials Market: Segment Analysis, Indication By Study Design, 2016 - 2028 (USD Million)
                    7.1. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
                        7.1.1. Autoimmune/inflammation
                            7.1.1.1. Interventional
                            7.1.1.2. Observational
                            7.1.1.3. Expanded Access
                        7.1.2. Pain management
                            7.1.2.1. Interventional
                            7.1.2.2. Observational
                            7.1.2.3. Expanded Access
                        7.1.3. Oncology
                            7.1.3.1. Interventional
                            7.1.3.2. Observational
                            7.1.3.3. Expanded Access
                        7.1.4. CNS condition
                            7.1.4.1. Interventional
                            7.1.4.2. Observational
                            7.1.4.3. Expanded Access
                        7.1.5. Diabetes
                            7.1.5.1. Interventional
                            7.1.5.2. Observational
                            7.1.5.3. Expanded Access
                        7.1.6. Obesity
                            7.1.6.1. Interventional
                            7.1.6.2. Observational
                            7.1.6.3. Expanded Access
                        7.1.7. Cardiovascular
                            7.1.7.1. Interventional
                            7.1.7.2. Observational
                            7.1.7.3. Expanded Access
                        7.1.8. Others
                            7.1.8.1. Interventional
                            7.1.8.2. Observational
                            7.1.8.3. Expanded Access
Chapter 8. Clinical Trials Market: Regional Market Analysis, By Phase, By Study Design, By Indication, 2016 - 2028 (USD Million)
                    8.1. Definitions & Scope
                    8.2. Regional Market Share Analysis, 2020 & 2028
                    8.3. Regional Market Dashboard
                    8.4. Regional Market Share, 2020
                    8.5. Market Size, & Forecasts, and Trend Analysis, 2016 to 2028:
                    8.6. North America
                        8.6.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
                        8.6.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                        8.6.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                        8.6.4. Market estimates and forecast, By Indication, 2016 - 2028 (USD Million)
                        8.6.5. U.S.
                            8.6.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.6.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.6.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.6.6. Canada
                            8.6.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.6.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.6.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                    8.7. Europe
                        8.7.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
                        8.7.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                        8.7.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                        8.7.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.7.5. Germany
                            8.7.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.7.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.7.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.7.6. U.K.
                            8.7.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.7.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.7.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.7.7. France
                            8.7.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.7.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.7.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.7.8. Italy
                            8.7.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.7.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.7.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.7.9. Spain
                            8.7.9.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.7.9.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.7.9.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                    8.8. Asia Pacific
                        8.8.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
                        8.8.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                        8.8.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                        8.8.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.8.5. China
                            8.8.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.8.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.8.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.8.6. Japan
                            8.8.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.8.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.8.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.8.7. India
                            8.8.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.8.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.8.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.8.8. Australia
                            8.8.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.8.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.8.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.8.9. South Korea
                            8.8.9.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.8.9.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.8.9.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                    8.9. Latin America
                        8.9.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
                        8.9.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                        8.9.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                        8.9.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.9.5. Brazil
                            8.9.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.9.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.9.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.9.6. Mexico
                            8.9.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.9.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.9.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.9.7. Argentina
                            8.9.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.9.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.9.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.9.8. Colombia
                            8.9.8.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.9.8.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.9.8.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                    8.10. Middle East and Africa
                            8.10.1. Market estimates and forecast, by country, 2016 - 2028 (USD Million)
                            8.10.2. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.10.3. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                        8.10.4. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.10.5. South Africa
                            8.10.5.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.10.5.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.10.5.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.10.6. Saudi Arabia
                            8.10.6.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.10.6.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.10.6.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
                        8.10.7. UAE
                            8.10.7.1. Market estimates and forecast, by phase, 2016 - 2028 (USD Million)
                            8.10.7.2. Market estimates and forecast, by study design, 2016 - 2028 (USD Million)
                            8.10.7.3. Market estimates and forecast, by indication, 2016 - 2028 (USD Million)
Chapter 9. Clinical Trials Market - Competitive Analysis
                    9.1. Key companies profiled
                        9.1.1. IQVIA
                            9.1.1.1. Company Overview
                            9.1.1.2. Financial Performance
                            9.1.1.3. Product Benchmarking
                            9.1.1.4. Strategic Initiatives
                        9.1.2. PAREXEL International Corporation
                            9.1.2.1. Company Overview
                            9.1.2.2. Financial Performance
                            9.1.2.3. Product Benchmarking
                            9.1.2.4. Strategic Initiatives
                        9.1.3. Pharmaceutical Product Development, LLC
                            9.1.3.1. Company Overview
                            9.1.3.2. Financial Performance
                            9.1.3.3. Product Benchmarking
                            9.1.3.4. Strategic Initiatives
                        9.1.4. Charles River Laboratory
                            9.1.4.1. Company Overview
                            9.1.4.2. Financial Performance
                            9.1.4.3. Product Benchmarking
                            9.1.4.4. Strategic Initiatives
                        9.1.5. ICON Plc
                            9.1.5.1. Company Overview
                            9.1.5.2. Financial Performance
                            9.1.5.3. Product Benchmarking
                            9.1.5.4. Strategic Initiatives
                        9.1.6. Wuxi AppTec Inc
                            9.1.6.1. Company Overview
                            9.1.6.2. Financial Performance
                            9.1.6.3. Product Benchmarking
                            9.1.6.4. Strategic Initiatives
                        9.1.7. PRA Health Sciences
                            9.1.7.1. Company Overview
                            9.1.7.2. Financial Performance
                            9.1.7.3. Product Benchmarking
                            9.1.7.4. Strategic Initiatives
                        9.1.8. SGS SA
                            9.1.8.1. Company Overview
                            9.1.8.2. Financial Performance
                            9.1.8.3. Product Benchmarking
                            9.1.8.4. Strategic Initiatives
                        9.1.9. Syneos Health
                            9.1.9.1. Company Overview
                            9.1.9.2. Financial Performance
                            9.1.9.3. Product Benchmarking
                            9.1.9.4. Strategic Initiatives
                        9.1.10. Chiltern International Ltd
                            9.1.10.1. Company Overview
                            9.1.10.2. Financial Performance
                            9.1.10.3. Product Benchmarking
                            9.1.10.4. Strategic Initiatives
                        9.1.11. Eli Lilly and Company
                            9.1.11.1. Company Overview
                            9.1.11.2. Financial Performance
                            9.1.11.3. Product Benchmarking
                            9.1.11.4. Strategic Initiatives
                        9.1.12. Novo Nordisk A/S
                            9.1.12.1. Company Overview
                            9.1.12.2. Financial Performance
                            9.1.12.3. Product Benchmarking
                            9.1.12.4. Strategic Initiatives
                        9.1.13. Pfizer
                            9.1.13.1. Company Overview
                            9.1.13.2. Financial Performance
                            9.1.13.3. Product Benchmarking
                            9.1.13.4. Strategic Initiatives
                        9.1.14. Clinipace
                            9.1.14.1. Company Overview
                            9.1.14.2. Financial Performance
                            9.1.14.3. Product Benchmarking
                            9.1.14.4. Strategic Initiatives


List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 Therapeutics in development
Table 4 Vaccines in development
Table 5 Vaccines in development for COVID-19
Table 6 Impact of COVID-19 on new patients entering trials
Table 7 Impact of COVID-19 on other therapeutic areas
Table 8 Strategic collaborations by key players
Table 9 Interventional studies
Table 10 Blood cancer clinical trials
Table 11 Medicines in development for neurological disorders, 2018
Table 12 Number of Alzheimer’s disease clinical trials, by phase
Table 13 Top 10 therapy areas by phase


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Clinical trials market snapshot (2020)
Fig. 10 Clinical trials market segmentation
Fig. 11 Clinical trials market: Strategy framework
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Virtual clinical trials
Fig. 16 Companies with affected trials, by size
Fig. 17 Affected trials, by study phase
Fig. 18 Market driver relevance analysis (Current & future impact)
Fig. 19 Market restraint relevance analysis (Current & future impact)
Fig. 20 Porter’s five forces analysis
Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 22 Clinical trials market phase outlook: Segment dashboard
Fig. 23 Clinical trials market: Phase movement analysis
Fig. 24 Phase I market, 2016 - 2028 (USD Million)
Fig. 25 Phase II market, 2016 - 2028 (USD Million)
Fig. 26 Phase III market, 2016 - 2028 (USD Million)
Fig. 27 Phase IV market, 2016 - 2028 (USD Million)
Fig. 28 Clinical trials market study design outlook: Segment dashboard
Fig. 29 Clinical trials market: Study design movement analysis
Fig. 30 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 31 Observational studies market, 2016 - 2028 (USD Million)
Fig. 32 Expanded access studies market, 2016 - 2028 (USD Million)
Fig. 33 Clinical trials market indication outlook: Segment dashboard
Fig. 34 Clinical trials market: Indication movement analysis
Fig. 35 Autoimmune clinical trial by phase, 2020 (%)
Fig. 36 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
Fig. 37 Rheumatoid arthritis clinical trial by phase (%)
Fig. 38 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
Fig. 39 Multiple sclerosis clinical trial by phase (%)
Fig. 40 Multiple sclerosis market, 2016 - 2028 (USD Million)
Fig. 41 Osteoarthritis clinical trials by phase (%)
Fig. 42 Osteoarthritis market, 2016 - 2028 (USD Million)
Fig. 43 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
Fig. 44 Others market, 2016 - 2028 (USD Million)
Fig. 45 Pain management market, 2016 - 2028 (USD Million)
Fig. 46 Chronic pain clinical trial by phase (%)
Fig. 47 Chronic pain market, 2016 - 2028 (USD Million)
Fig. 48 Acute pain clinical trial by phase (%)
Fig. 49 Acute pain market, 2016 - 2028 (USD Million)
Fig. 50 Oncology market, 2016 - 2028 (USD Million)
Fig. 51 Blood cancer market, 2016 - 2028 (USD Million)
Fig. 52 Solid tumors market, 2016 - 2028 (USD Million)
Fig. 53 Others market, 2016 - 2028 (USD Million)
Fig. 54 CNS conditions market, 2016 - 2028 (USD Million)
Fig. 55 Epilepsy market, 2016 - 2028 (USD Million)
Fig. 56 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
Fig. 57 Huntington's disease market, 2016 - 2028 (USD Million)
Fig. 58 Stroke market, 2016 - 2028 (USD Million)
Fig. 59 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2016 - 2028 (USD Million)
Fig. 61 Muscle regeneration market, 2016 - 2028 (USD Million)
Fig. 62 Others market, 2016 - 2028 (USD Million)
Fig. 63 Diabetes market, 2016 - 2028 (USD Million)
Fig. 64 Obesity clinical trial by phase (%)
Fig. 65 Obesity market, 2016 - 2028 (USD Million)
Fig. 66 Cardiovascular market, 2016 - 2028 (USD Million)
Fig. 67 Others indications market, 2016 - 2028 (USD Million)
Fig. 68 Autoimmune/inflammation interventional studies market, 2016 - 2028 (USD Million)
Fig. 69 Autoimmune/inflammation observational studies market, 2016 - 2028 (USD Million)
Fig. 70 Autoimmune/inflammation expanded access market, 2016 - 2028 (USD Million)
Fig. 71 Pain management interventional studies market, 2016 - 2028 (USD Million)
Fig. 72 Pain management observational studies market, 2016 - 2028 (USD Million)
Fig. 73 Pain management expanded access market, 2016 - 2028 (USD Million)
Fig. 74 Oncology interventional studies market, 2016 - 2028 (USD Million)
Fig. 75 Oncology observational studies market, 2016 - 2028 (USD Million)
Fig. 76 Oncology expanded access market, 2016 - 2028 (USD Million)
Fig. 77 CNS conditions interventional studies market, 2016 - 2028 (USD Million)
Fig. 78 CNS conditions observational studies market, 2016 - 2028 (USD Million)
Fig. 79 CNS conditions expanded access market, 2016 - 2028 (USD Million)
Fig. 80 Diabetes interventional studies market, 2016 - 2028 (USD Million)
Fig. 81 Diabetes observational studies market, 2016 - 2028 (USD Million)
Fig. 82 Diabetes expanded access market, 2016 - 2028 (USD Million)
Fig. 83 Obesity interventional studies market, 2016 - 2028 (USD Million)
Fig. 84 Obesity observational studies market, 2016 - 2028 (USD Million)
Fig. 85 Obesity expanded access market, 2016 - 2028 (USD Million)
Fig. 86 Cardiovascular interventional studies market, 2016 - 2028 (USD Million)
Fig. 87 Cardiovascular observational studies market, 2016 - 2028 (USD Million)
Fig. 88 Cardiovascular expanded access market, 2016 - 2028 (USD Million)
Fig. 89 Others interventional studies market, 2016 - 2028 (USD Million)
Fig. 90 Others observational studies market, 2016 - 2028 (USD Million)
Fig. 91 Others expanded access market, 2016 - 2028 (USD Million)
Fig. 92 Regional market: Key takeaways
Fig. 93 Regional market share, 2020
Fig. 94 Regional outlook, 2020 & 2028
Fig. 95 North America market, 2016 - 2028 (USD Million)
Fig. 96 U.S. market, 2016 - 2028 (USD Million)
Fig. 97 Canada market, 2016 - 2028 (USD Million)
Fig. 98 Europe market, 2016 - 2028 (USD Million)
Fig. 99 U.K. market, 2016 - 2028 (USD Million)
Fig. 100 Germany market, 2016 - 2028 (USD Million)
Fig. 101 France market, 2016 - 2028 (USD Million)
Fig. 102 Italy market, 2016 - 2028 (USD Million)
Fig. 103 Spain market, 2016 - 2028 (USD Million)
Fig. 104 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 105 India market, 2016 - 2028 (USD Million)
Fig. 106 Japan market, 2016 - 2028 (USD Million)
Fig. 107 China market, 2016 - 2028 (USD Million)
Fig. 108 Australia market, 2016 - 2028 (USD Million)
Fig. 109 South Korea market, 2016 - 2028 (USD Million)
Fig. 110 Latin America market, 2016 - 2028 (USD Million)
Fig. 111 Brazil market, 2016 - 2028 (USD Million)
Fig. 112 Mexico market, 2016 - 2028 (USD Million)
Fig. 113 Argentina market, 2016 - 2028 (USD Million)
Fig. 114 Colombia market, 2016 - 2028 (USD Million)
Fig. 115 MEA market, 2016 - 2028 (USD Million)
Fig. 116 South Africa market, 2016 - 2028 (USD Million)
Fig. 117 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 118 UAE market, 2016 - 2028 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.